ライフサイエンスコーパス: costimulator

1 ted the ability of rhIL-4 to act as a T cell costimulator.

2 ng both forkhead box protein 3 and inducible costimulator.

3 whether Tim-1 can have a dual function as a costimulator.

4 , CD137 (4-1BB), CD134 (OX40), and inducible costimulator.

5 eplaced by reagents binding inducible T-cell costimulators.

6 ells and does not depend on MHC molecules or costimulators.

7 e lung with elevated expression of inducible costimulator a marker of T cell activation, and of T1/ST

8 Selective inducible costimulator activation (P < .001) was seen in children.

9 t for alloimmunity, including MHC molecules, costimulators, adhesion molecules, cytokines, chemokines

10 To facilitate this type of quantitative costimulator analysis, we developed a novel two-step pro

11 entified TL1A, an endothelium-derived T cell costimulator and a ligand for tumor necrosis factor rece

12 rface Daf protein function respectively as a costimulator and a negative modulator of T cell immunity

13 tudy demonstrates that CD55 acts as a potent costimulator and activator of human naive CD4(+) cells,

14 ation to splenic T cells via an unidentified costimulator and ICAM-1.

15 turation was manifest by marked increases in costimulator and major histocompatibility complex class

16 D-L2, CD40, CD80, CD86, and inducible T cell costimulator, and of major histocompatibility complex cl

17 on of live tumor cells to express cytokines, costimulators, and surrogate foreign antigens.

18 We found that both antibody to inducible costimulator (anti-ICOS) and an ICOS-Ig fusion protein s

19 The effects of these costimulators are overlapping but not identical.

20 T cells ectopically expressing costimulators are pathogenic and contribute to autoimmun

21 cells possessed B7-2 genes and expressed the costimulators as surface molecules, we propose that T ce

22 n advantage of the strong CTL responses to a costimulator B7-1-transfected tumor to study the mechani

23 tory tract enhance surface expression of the costimulator B7-2 (CD86) within 24-48 h following infect

24 e modulation of the expression of the T cell costimulator B7-H2 by GECs.

25 Coexpression of the costimulator B7.1 and the Tag oncoprotein leads to destr

26 ritis, we found that KTC did not express the costimulators B7-1 or B7-2.

27 The costimulator, B7-2, was required for optimum activation

28 ressed, ICOS did not act as a general T cell costimulator but selectively caused a massive expansion

29 ot only can ICAM-1 act as a CD28-independent costimulator, but it is the dominant, requisite costimul

30 Human ECs do not express B7 costimulators, but Nef- replication in CD4(+)-T-cell and

31 s of T cell division in comparison to single costimulators, but rather enhanced accumulation in a cel

32 es that arming tumor-reactive T cells with a costimulator can enhance their antitumor efficacy.

33 eceptors were generated with CD28, inducible costimulator, CD134, or CD137 signaling regions in serie

34 Contemporaneously, the costimulator CD27 was down-regulated.

35 prosurvival effects of the TNF-R superfamily costimulator CD27.

36 potent than those mediated by the "classic" costimulator CD28.

37 Significantly, this "tetra-costimulator" combination, delivered intratumorally, ind

38 Furthermore, several recently described costimulators contribute to these processes.

39 B-cell lymphoma 6, IL-21, inducible costimulator, CXCR5, and programmed cell death protein 1

40 tin-1 antagonizes Ag induced signals and TCR/costimulator dependent lipid raft clustering at the TCR

41 s with preformed conjugates of a murine B7-1 costimulator derivative, B7-1.Fc(gamma1), and pal-prot A

42 Strikingly, MRL-Faslpr mice lacking both B7 costimulators do not develop kidney (glomerular, tubular

43 Blockade of these costimulators each partially reduces IFN-gamma and IL-2

44 ibility complex (MHC) class II molecules and costimulators, EC-stimulated virus-producing cells (p24(

45 assays were used to evaluate the role of B7 costimulators expressed by CMFs with regard to the regul

46 New evidence shows that negative costimulators expressed by tumors and normal tissues aff

47 sion protein derivatives of three additional costimulators (Fc(gamma1).4-1BBL, CD48.Fc(gamma1), and F

48 molecule, a cell surface protein which is a costimulator for T cell activation.

49 like rhIL-4, rhIL-4 delta 2 did not act as a costimulator for T cell proliferation.

50 tions as a pathogen receptor and is a potent costimulator for the induction of interferon-gamma (IFN-

51 timulation and the relative importance of B7 costimulators for the induction and effector phases of e

52 into cell membranes by this method retained costimulator function, as measured by an in vitro prolif

53 led from signals that promote maturation and costimulator function.

54 We and others have proposed that costimulators function to construct a raft-based platfor

55 Thus, constitutively expressed B7 costimulators function to suppress T cell activation and

56 Various cytokines and costimulators have been identified which regulate expres

57 cytometry was used to measure CD69/inducible costimulator/HLA-DR frequency in memory cell subsets, as

58 ating signaling intensity from the inducible costimulator ICOS and kinase PI(3)K by suppressing expre

59 Signaling via the inducible costimulator ICOS fuels the stepwise development of foll

60 of CD40-ligand (CD40L) and inducible T-cell costimulator (ICOS) (both P < 0.001) and decreased produ

61 Inducible costimulator (ICOS) and B7-related protein-1 (B7RP-1) co

62 Interaction between inducible costimulator (ICOS) and its ligand is implicated in the

63 c T lymphocyte antigen 4 (CTLA-4), inducible costimulator (ICOS) and PD-1.

64 Using inducible costimulator (ICOS) as a model, we failed to find any pr

65 d chemokine receptor 5 (CXCR5) and inducible costimulator (ICOS) at low levels (CXCR5(lo)ICOS(lo)), a

66 ulating GC selection by increasing inducible costimulator (ICOS) expression on TFH cells and reducing

67 Inducible costimulator (ICOS) has been suggested to perform an imp

68 r and cooperation between CD28 and inducible costimulator (ICOS) in effective T helper (TH) cell resp

69 ells exhibit decreased and delayed inducible costimulator (ICOS) induction and heightened CD40L expre

70 T cells with a CAR containing the inducible costimulator (ICOS) intracellular domain generates tumor

71 Inducible costimulator (ICOS) is a new member of the CD28/CTLA-4 f

72 Inducible costimulator (ICOS) is a novel costimulatory receptor ex

73 The inducible T cell costimulator (ICOS) is a potent promoter of organ inflam

74 Inducible costimulator (ICOS) is a recently identified costimulato

75 Inducible costimulator (ICOS) is expressed on activated and memory

76 Expression of the inducible costimulator (ICOS) is increased in TSC1-deficient T cel

77 The inducible costimulator (ICOS) is the newest member of the CD28/CD1

78 Inducible costimulator (ICOS) is the third member of the CD28/CTLA

79 Inducible costimulator (ICOS) ligand (ICOSL), a B7-related transme

80 rgely a result of up-regulation of inducible costimulator (ICOS) ligand on TACI-deficient B cells, gi

81 requency of T cells expressing the inducible costimulator (ICOS) molecule, a T-cell-specific molecule

82 B7h interacts with inducible costimulator (ICOS) on T cells and provides a positive s

83 The inducible costimulator (ICOS) plays a key role in the development

84 We demonstrate that inducible costimulator (ICOS) provides a critical early signal to

85 igher levels of interleukin 10 and inducible costimulator (ICOS) than their lymph node counterparts.

86 Inducible costimulator (ICOS), a CD28/cytotoxic T lymphocyte antig

87 Inducible costimulator (ICOS), a member of the CD28 family of cost

88 Inducible costimulator (ICOS), a member of the CD28 family of cost

89 le expressed on activated T cells, inducible costimulator (ICOS), and its ligand, B7-related protein-

90 escribed ligand-receptor pair, B7h-inducible costimulator (ICOS), is critical for germinal center for

91 whether a costimulatory receptor, inducible costimulator (ICOS), is involved in NK cell function, we

92 associated molecules IL-10, inducible T-Cell costimulator (ICOS), lymphocyte activation gene 3 protei

93 le of novel costimulatory molecule-inducible costimulator (ICOS), OX40, 4-1BB, and CD27 in mediating

94 n a fashion dependent on IL-21 and inducible costimulator (ICOS), thus sharing fundamental characteri

95 gulation of CD40L, PD-1, and inducibl T-cell costimulator (ICOS), which may favor the accumulation of

96 ata reveal the necessity of inducible T-cell costimulator (ICOS)-ICOS ligand cell contact for Treg ce

97 vent fibrosis is controlled by the inducible costimulator (ICOS)-ICOS ligand pathway.

98 sion of bound target mRNAs such as inducible costimulator (Icos).

99 lymphocyte antigen-4 (CTLA-4), and inducible costimulator (ICOS).

100 ally related proteins CD28 and the inducible costimulator (ICOS).

101 r CD4, CD25, Foxp3, and the inducible T cell costimulator (ICOS).

102 of Foxp3(+) Treg cells expressing inducible costimulator (ICOS).

103 d markedly increased expression of inducible costimulator (ICOS).

104 king mAbs for IL-21/IL-21R, inducible T-cell costimulator (ICOS)/ICOS ligand, and CD40L/CD40 hindered

105 A>G), Fas ligand (fasL, -844 C>T), inducible costimulator (ICOS, 3990 G>T), interleukin-6 (IL-6, -174

106 uired T-cell costimulation via the inducible costimulator (ICOS-ICOS-ligand pathway.

107 yte-associated antigen 4 [CTLA-4], inducible costimulator [ICOS], program death-1 [PD-1], and B- and

108 ls and the binding is abrogated by inducible costimulator Ig (ICOSIg), but not CTLA4Ig.

109 ry response, we have both expressed a potent costimulator in oncogene-expressing beta cells and incre

110 revealed a requirement for the CD5 and CD28 costimulators in autoantigen-induced deletion.

111 ed strong evidence for the action of several costimulators in negative selection, we wished to demons

112 antibody to transiently block the inducible costimulator/inducible costimulator ligand (ICOS/ICOSL)

113 est that an extraordinarily complex array of costimulators is involved in negative selection.

114 pDCs upregulate the expression of inducible costimulator ligand (ICOS-L) and maintain high expressio

115 hat human melanomas express inducible T-cell costimulator ligand (ICOS-L/B7H) that can provide costim

116 y block the inducible costimulator/inducible costimulator ligand (ICOS/ICOSL) signaling pathway led t

117 were given isotype or anti-inducible T-cell costimulator ligand (ICOSL) antibodies and then challeng

118 ptor regulate B-cell expression of inducible costimulator ligand (ICOSL), a molecule required for Tfh

119 ll death-2 ligand [PD-L2]), CD275 (inducible costimulator ligand [ICOS-L]), CD276 (B7-H3), B7-H4, and

120 other immune regulatory molecules (inducible costimulator ligand and glucocorticoid-induced tumor nec

121 the response is completely inducible T-cell costimulator ligand independent.

122 the Bcl6 transcription factor and inducible costimulator ligand on B cells.

123 IL-27, IL-10, and inducible T-cell costimulator ligand signaling are essential for CD1c(+)D

124 f the cell-surface receptor inducible T-cell costimulator ligand that promotes optimal interactions b

125 h ligands, OX40 ligand, and inducible T-cell costimulator ligands were not implicated.

126 ation blockade using CD154 or anti-inducible costimulator mAb.

127 infections were multiple other cytokines and costimulators may be up-regulated.

128 adhesion, up-regulation of MHC class II and costimulator molecule expression, and acquisition of enh

129 CD40 ligand (CD40L) is a costimulator molecule that directly activates T cells an

130 However, lack of expression of conventional costimulator molecules means that these cells tend to in

131 ss-links multiple cell surface receptors and costimulator molecules on human T cells.

132 xpand in vivo, presumably due to the lack of costimulator molecules on tumor cells and the inherent l

133 ic beta cells, which do not normally express costimulator molecules, converts the cells into effectiv

134 ession of peptide-class II MHC complexes and costimulator molecules.

135 uman B7-H3 was first described as a positive costimulator, most potently inducing IFN-gamma productio

136 Several recently identified costimulators, namely, 4-1BB ligand, ICOS ligand, and OX

137 cordingly, we examined thymocyte deletion in costimulator-null mice in three models of autoantigen-in

138 yte stimulator (BLyS) is a well-known direct costimulator of adaptive immune cells, particularly B li

139 on of TS1 in platelets is that of a secreted costimulator of alphaIIbbeta3 whose unique properties re

140 Therefore, 2B4 functions as a costimulator of CD8(+) T cells in MHC-restricted cytotox

141 These data identify CD55 as a novel costimulator of human Tr1s and support a role for altern

142 1A is a novel TNF-like factor that acts as a costimulator of IFN-gamma secretion through binding to t

143 of an agonist antibody to CD40, an important costimulator of immune function, in combination with int

144 Flt3/flk-2 ligand (flt3-L) is a potent costimulator of normal bone marrow (BM) myeloid progenit

145 s ligand is therefore an inducer of death, a costimulator of peripheral T cell activation, and an acc

146 We show that thalidomide is a potent costimulator of primary human T cells in vitro, synergiz

147 IL-12, a costimulator of Th1 having no proliferation-inducing cap

148 was a concomitant response to IL-1, a known costimulator of Th2.

149 Our data designate CXCR4 as a costimulator of the pre-TCR during beta-selection.

150 roducers of IgG1, IgG2a, and IgG2b, and weak costimulators of CD4(+) Tconv proliferation.

151 Moreover, circulating monocytes were potent costimulators of IL-9 production by Th17 cells via their

152 TNFRSF4 agonists were potent costimulators of OVA/aluminum hydroxide-induced CD4(+) T

153 he TNF receptor superfamily (TNFRSF) are key costimulators of T cells during infection, and there has

154 ction, whereas TNFRSF25 agonists were strong costimulators of Treg proliferation, producers of IgG1,

155 tegy to establish that the levels of surface costimulator on APCs can dictate both the magnitude and

156 Here we show that SLAMF3 functions as a costimulator on CD4(+) T cells and influences IL-2 respo

157 especially upregulation of inducible T-cell costimulator on T cells, together with severely disturbe

158 ntigens, we hypothesize that neoexpressing a costimulator on tumor-reactive T cells may likewise enha

159 ts T cell function by acting as an intrinsic costimulator or by induction of other costimulatory mole

160 Inclusion of CD28, inducible costimulator, or CD134 enhanced TCRzeta-mediated, Ag-spe

161 novirus Delta-24-RGDOX expressing the immune costimulator OX40 ligand (OX40L).

162 ternative costimulatory receptors (inducible costimulator, OX40, 4-1BB, cytotoxic T lymphocyte associ

163 ly impaired upregulation of inducible T-cell costimulator, OX40, cytokine production, proliferation o

164 increased T-cell expression of the negative costimulator PD-1 recently has been postulated to contri

165 IL-35 production by inducible costimulator-positive Treg cells can suppress IL-17 prod

166 cell activation by class II MHC antigens and costimulators (principally lymphocyte function-associate

167 dy, we reveal a crucial role of the negative costimulator programmed death-1 (PD-1) in regulating dev

168 The CD28 family member inducible costimulator protein (ICOS) has an important role in T c

169 cation of the B7-related protein 1/inducible costimulator protein (ICOS) pathway and its ability to r

170 tion of antitumor immunity via combinatorial costimulator protein transfer on to tumor cell surfaces.

171 The notion of costimulator receptor activation thresholds emerges.

172 In this study, we find that the 4-1BB costimulator receptor, best known for promoting the prol

173 mparable activation thresholds exist for the costimulator receptors on T cells.

174 pendent upon coordinate engagement of Ag and costimulator receptors on their surfaces.

175 l-costimulatory molecules CD28 and inducible costimulator recruit and activate class 1A phosphoinosit

176 y of anti-tumor necrosis factor agents and a costimulator signal inhibitor.

177 eas CD40/CD40L interactions provide critical costimulator signals for T-cell-dependent immune respons

178 lability of IL-2, and accessory cell or CD28 costimulator signals.

179 It is reported that the CD86 costimulator significantly affects disease outcome in Le

180 gh PD-1 can overcome the ability of positive costimulators, such as CD2 and CD28, to facilitate posit

181 nt finding that thalidomide acts as a T cell costimulator suggested that this drug may boost antivira

182 d the frequency of ICOS(+) (inducible T-cell costimulator) Tfh-like cells in blood.

183 actor (TNF)-like cytokine (TL1A) is a T-cell costimulator that bolsters cytokine-induced activation t

184 e results identify IL-15 as an indispensable costimulator that can determine the functional fate of a

185 Interestingly, in T cells, TL1A acts as a costimulator that increases IL-2 responsiveness and secr

186 nistic analysis of a newly emerging group of costimulators, the TNF family.

187 ent years by the identification of different costimulators, this classical pathway has been shown to

188 induce T-cell proliferation alone but act as costimulators to trigger proliferation of anti-CD3-stimu

189 We now show that in the absence of costimulators, TRAIL induction on pDCs occurs with agoni

190 Hence, combinatorial costimulator transfer, coupled to intratumoral delivery,

191 B7-H2, best known as the ligand of inducible costimulator, was a ligand for CD28 and CTLA-4 in human,

192 We predict that different sets of costimulators will be required depending on the timing o

193 t of autoimmunity, and functions as a potent costimulator with antiimmunoglobulin M in B cell prolife

194 is review, we will discuss this new class of costimulators with a focus on the mechanism of costimula